ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$15.14 USD
-0.59 (-3.75%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $15.22 +0.08 (0.53%) 6:42 PM ET
3-Hold of 5 3
B Value A Growth D Momentum A VGM
Brokerage Reports
ACADIA Pharmaceuticals Inc. [ACAD]
Reports for Purchase
Showing records 1 - 20 ( 246 total )
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Intranasal Oxytocin Therapy Can Be Effective in PWS - Our Thoughts; PT to $27
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Shifting Focus to ACP-204 and ACP-101, the Key Value Drivers in the Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Arvinas Enters the Neurodegeneration Space With LRRK2
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Positive Data from ADVANCE-2 Potentially Allow Pimavanserin to be Marketed as the First Drug for Negative Symptoms
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department